Quick Search 
Journals Home
Drugs of Today
Issues
Drugs of Today
Policies & Guidelines
Permissions
My
Profile
Contact
Us
Shopping
Cart
Purchase
History
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2016, 52(2): 97
ISSN 1699-3993
e-ISSN 1699-4019
Copyright 2016 Clarivate
CCC: 1699-3993
DOI: 10.1358/dot.2016.52.2.2461868		 
 
Cariprazine: New dopamine biased agonist for neuropsychiatric disorders
De Deurwaerdere, P.		 
 
Cariprazine (RGH-188, MP-214, Vraylar[TM]) is a new dopamine receptor ligand developed for the treatment of several neuropsychiatric diseases including schizophrenia and bipolar disorders. Cariprazine displays higher affinity at dopamine D3 receptors and a similar affinity at D2 and 5-HT2B receptors. At variance with some atypical antipsychotics, its affinity at 5-HT1A, 5-HT2A and histamine H1 receptors is modest compared with its three main targets. Cariprazine could correspond to a biased agonist at dopamine receptors, displaying either antagonist or partial agonist properties depending on the signaling pathways linked to D2/D3 receptors. The compound crosses the blood-brain barrier, as revealed by positron emission tomography and pharmacokinetic studies in various species. Two main metabolites result mainly from the activity of CYP34A and display properties similar to those of the parent drug. Behavioral data report that cariprazine is efficacious in animal models addressing positive, negative and cognitive symptoms of schizophrenia with no extrapyramidal side effects. In September 2015, the FDA approved the use of cariprazine for the treatment of schizophrenia and type I bipolar disorder. The efficacy of cariprazine in other neuropsychiatric diseases is currently being evaluated in preclinical and clinical studies. Side effects have been observed in humans, including extrapyramidal side effects and akathisia of mild to moderate intensity.


Full Text: PDF 		 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences